Deal Tracker · Countries

Saudi Arabia pharma licensing deals

24 licensing deals involving Saudi Arabia tracked by EPT (2014–2026). Most active: ADCAN Pharma, Bio-Thera Solutions, Jamjoom Pharma & Avalon Pharma. Latest: Bukwang Pharmaceutical → NASAQ (Licensing, 4 Nov 2026).

24
deals tracked
17
announced in 2026
$96.7m
disclosed value (2 deals)
100%
licensing, the top deal type
  • EPT has tracked 24 Saudi Arabia pharma licensing deals (2014–2026), 17 of them announced in 2026.
  • The countries that appear most often are China (7), UAE (7), India (4) & Greece (3).
  • Values were disclosed for 2 of 24 deals, totalling $96.7m; the largest is Daewoong Pharmaceutical → Arcera Life Sciences ($94m, 29 Jun 2026).
  • The most active companies: ADCAN Pharma (6), Bio-Thera Solutions (4), Jamjoom Pharma (4) & Avalon Pharma (3).

Most active companies

ADCAN Pharma (6) · Bio-Thera Solutions (4) · Jamjoom Pharma (4) · Avalon Pharma (3) · SPIMACO (3) · Tabuk Pharmaceuticals (3)

Countries involved

China (7) · UAE (7) · India (4) · Greece (3) · Iraq (2) · South Korea (2)

Largest disclosed deals

Questions

How many Saudi Arabia pharma licensing deals has EPT tracked?
24 as of 4 Nov 2026, covering 2014–2026; 17 were announced in 2026. The most recent is Bukwang Pharmaceutical → NASAQ (Licensing, 4 Nov 2026).
Which companies are most active in Saudi Arabia pharma licensing deals?
ADCAN Pharma (6 deals), Bio-Thera Solutions (4 deals), Jamjoom Pharma (4 deals), Avalon Pharma (3 deals), SPIMACO (3 deals), Tabuk Pharmaceuticals (3 deals).
What is the largest disclosed Saudi Arabia pharma licensing deal?
Daewoong Pharmaceutical → Arcera Life Sciences: $94m (Licensing, 29 Jun 2026); Bukwang Pharmaceutical → NASAQ: $2.7m (Licensing, 4 Nov 2026). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)